Suppr超能文献

体外扩增的端粒酶特异性T细胞在胰腺腺癌原位小鼠模型中具有疗效。

Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma.

作者信息

Hassanin H, Serba S, Schmidt J, Märten A

机构信息

Department of Surgery, University of Heidelberg, Heidelberg, Germany.

出版信息

Clin Exp Immunol. 2009 Oct;158(1):125-32. doi: 10.1111/j.1365-2249.2009.03935.x.

Abstract

Telomerase activity is over-expressed in nearly all pancreatic carcinomas, but not in chronic pancreatitis. Here, we investigated various protocols for expansion of telomerase-specific T cells for adoptive cell transfer and their use in a syngeneic pancreatic carcinoma mouse model. Telomerase-specific T cells were generated by stimulation of splenocytes from peptide-immunized donor mice with either interleukin (IL)-2, IL-15, artificial antigen-presenting cells, anti-signalling lymphocyte activation molecule (SLAM) microbeads or allogeneic dendritic cells in combination with a limited dilution assay. T cells were tested for antigen specificity in vitro and for anti-tumour activity in syngeneic mice with orthotopically implanted tumours pretreated with cyclophosphamide. The immune cells from recipients were immunophenotyped. During a period of 2 weeks, the expansion approach using IL-2 was very successful in generating a high number of telomerase-specific CD8(+) T cells without losing their function after adoptive cell transfer. Significantly slower tumour growth rate and less metastasis were observed after adoptively transferring telomerase specific CD8(+) T cells, expanded using IL-2. Further investigations showed that anti-tumour efficacy was associated with a significant shift from naive CD8(+) T cells to CD8(+) central memory T cells, as well as recruitment of a high number of dendritic cells. Remarkable amounts of telomerase-specific T cells were detectable in the tumour. Generation of telomerase-specific T cells is feasible, whereat IL-2-based protocols seemed to be most effective and efficient. Antigen-specific T cells showed significant cytotoxic activity in a syngeneic, orthotopic mouse model, whereas central memory T cells but not effector memory T cells appear to be of high importance.

摘要

端粒酶活性在几乎所有胰腺癌中均过度表达,但在慢性胰腺炎中则不然。在此,我们研究了用于扩增端粒酶特异性T细胞以进行过继性细胞转移的各种方案,以及它们在同基因胰腺癌小鼠模型中的应用。通过用白细胞介素(IL)-2、IL-15、人工抗原呈递细胞、抗信号淋巴细胞激活分子(SLAM)微珠或同种异体树突状细胞刺激来自肽免疫供体小鼠的脾细胞,并结合有限稀释分析来产生端粒酶特异性T细胞。在体外测试T细胞的抗原特异性,并在经环磷酰胺预处理的原位植入肿瘤的同基因小鼠中测试其抗肿瘤活性。对受体的免疫细胞进行免疫表型分析。在2周的时间内,使用IL-2的扩增方法在产生大量端粒酶特异性CD8(+) T细胞方面非常成功,且过继性细胞转移后其功能未丧失。过继性转移使用IL-2扩增的端粒酶特异性CD8(+) T细胞后,观察到肿瘤生长速率显著减慢且转移减少。进一步研究表明,抗肿瘤疗效与从初始CD8(+) T细胞向CD8(+) 中央记忆T细胞的显著转变以及大量树突状细胞的募集有关。在肿瘤中可检测到大量端粒酶特异性T细胞。产生端粒酶特异性T细胞是可行的,基于IL-2的方案似乎最为有效。抗原特异性T细胞在同基因原位小鼠模型中显示出显著的细胞毒性活性,而中央记忆T细胞而非效应记忆T细胞似乎至关重要。

相似文献

3
Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo.
Cancer. 2006 Feb 15;106(4):759-64. doi: 10.1002/cncr.21655.

引用本文的文献

1
The dark side of immunotherapy: pancreatic cancer.免疫疗法的阴暗面:胰腺癌
Cancer Drug Resist. 2020 May 11;3(3):491-520. doi: 10.20517/cdr.2020.13. eCollection 2020.
2
Emerging trends in the immunotherapy of pancreatic cancer.胰腺癌免疫治疗的新趋势。
Cancer Lett. 2018 Mar 28;417:35-46. doi: 10.1016/j.canlet.2017.12.012. Epub 2017 Dec 12.
3
BPTF Depletion Enhances T-cell-Mediated Antitumor Immunity.BPTF缺失增强T细胞介导的抗肿瘤免疫。
Cancer Res. 2016 Nov 1;76(21):6183-6192. doi: 10.1158/0008-5472.CAN-15-3125. Epub 2016 Sep 20.

本文引用的文献

2
Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP.CD150和SAP在体内外增强抗肿瘤活性
Mol Immunol. 2008 Feb;45(3):796-804. doi: 10.1016/j.molimm.2007.06.361. Epub 2007 Aug 10.
5
Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo.
Cancer. 2006 Feb 15;106(4):759-64. doi: 10.1002/cncr.21655.
9
Detection of telomerase activity in patients with pancreatic cancer.
Methods Mol Med. 2005;103:199-205. doi: 10.1385/1-59259-780-7:199.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验